These results suggested eGDR is a more valuable IR biomarker in predicting ASCVD diagnosis and new-onset ASCVD risk, offering novel insights into ASCVD prevention strategies through improving glucose utilization capability and insulin sensitivity. This evidence concerns the gene INS and atherosclerosis.